2
项与 CD133+ autologous bone marrow stem cell(Miltenyi Biotec B.V. & Co. KG) 相关的临床试验Evaluating the safety of autologous intra papillary muscle injection of bone marrow stem cell in patients with up to moderate ischemic mitral regurgitation: A Phase II clinical trial
Intramyocardial Transplantation of Bone Marrow Stem Cells for Improvement of Post-infarct Myocardial Regeneration in Addition to CABG Surgery: a Controlled, Prospective, Randomized, Double Blinded Multicenter Trial (PERFECT)
In spite of the fact that the post-myocardial infarction survival rate has improved with recent medical advances, reduced heart function attributed to irreversible loss of viable cardiomyocytes is still a major clinical problem.
The aim of the current study is to determine whether intramyocardial injection of autologous CD133+ bone marrow stem cells yields a functional benefit in addition to coronary artery bypass graft (CABG) surgery in patients with chronic ischemic coronary artery disease.
100 项与 CD133+ autologous bone marrow stem cell(Miltenyi Biotec B.V. & Co. KG) 相关的临床结果
100 项与 CD133+ autologous bone marrow stem cell(Miltenyi Biotec B.V. & Co. KG) 相关的转化医学
100 项与 CD133+ autologous bone marrow stem cell(Miltenyi Biotec B.V. & Co. KG) 相关的专利(医药)
100 项与 CD133+ autologous bone marrow stem cell(Miltenyi Biotec B.V. & Co. KG) 相关的药物交易